This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tewksbury, D. A. Articles by Dart, R. A. Search for Related Content PubMed PubMed Citation Articles by Tewksbury, D. A. Articles by Dart, R. A.

Hypertension, Vol 4, 729-734, Copyright © 1982 by American Heart Association

ARTICLES

High molecular weight angiotensinogen levels in hypertensive pregnant women

DA Tewksbury and RA Dart

An apparent high molecular weight angiotensinogen (H-Aogen) can be separated from the usually predominant low molecular weight angiotensinogen (L-Aogen) by gel filtration of plasma. H-Aogen has been quantitated in plasma from normotensive menstruating women, estrogen treated women, normotensive pregnant women, women with pregnancy- induced hypertension (PIH), and women whose preexisting hypertension was exacerbated during pregnancy. When expressed as a percent of the total angiotensinogen, the H-Aogen levels were: menstruating women 4%, estrogen-treated women 10%, normotensive pregnant women 16%, women with PIH 25%, and pregnant women with exacerbated hypertension 28%. A significant difference (p less than 0.01) was found between H-Aogen concentration in normotensive pregnant women and women with PIH (1.10 +/- 0.12 and 1.73 +/- 0.16 micrograms angiotensin I/ml plasma respectively). In some hypertensive pregnant women, H-Aogen is the predominant form of angiotensinogen. Thus, H-Aogen should be recognized as a component of the renin-angiotensin system.

This article has been cited by other articles:

				J. R. Lindsay and L. K. Nieman The Hypothalamic-Pituitary-Adrenal Axis in Pregnancy: Challenges in Disease Detection and Treatment Endocr. Rev., October 1, 2005; 26(6): 775 - 799. [Abstract] [Full Text] [PDF]

				H. KOBORI, L. M. HARRISON-BERNARD, and L. G. NAVAR Expression of Angiotensinogen mRNA and Protein in Angiotensin II-Dependent Hypertension J. Am. Soc. Nephrol., March 1, 2001; 12(3): 431 - 439. [Abstract] [Full Text]

				R. S. Cooper, X. Guo, C. N. Rotimi, A. Luke, R. Ward, A. Adeyemo, and S. M. Danilov Heritability of Angiotensin-Converting Enzyme and Angiotensinogen : A Comparison of US Blacks and Nigerians Hypertension, May 1, 2000; 35(5): 1141 - 1147. [Abstract] [Full Text] [PDF]

				A.-P. Gimenez-Roqueplo, J. Celerier, G. Schmid, P. Corvol, and X. Jeunemaitre Role of Cysteine Residues in Human Angiotensinogen. CYS232 IS REQUIRED FOR ANGIOTENSINOGEN-PRO MAJOR BASIC PROTEIN COMPLEX FORMATION J. Biol. Chem., December 18, 1998; 273(51): 34480 - 34487. [Abstract] [Full Text] [PDF]

				P. Corvol and X. Jeunemaitre Molecular Genetics of Human Hypertension: Role of Angiotensinogen Endocr. Rev., October 1, 1997; 18(5): 662 - 677. [Abstract] [Full Text]

				L. D. Atwood, C. M. Kammerer, P. B. Samollow, J. E. Hixson, R. E. Shade, and J. W. MacCluer Linkage of Essential Hypertension to the Angiotensinogen Locus in Mexican Americans Hypertension, September 1, 1997; 30(3): 326 - 330. [Abstract] [Full Text]